2022 ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2022-05-07±³À°ÀÏÀÚ : 2022-05-07
±³À°Àå¼Ò : ±×·£µå ¿öÄ¿Èú ¼¿ï
±³À°ÁÖÁ¦ :
2022 ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ
´ã´çÀÚ : Á¤ÃáÈñ
¿¬¶ôó : 02-747-0528
À̸ÞÀÏ :
korall@chol.com ±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, À̺ñÀÎÈÄ°ú, ÇǺΰú, °¡Á¤ÀÇÇаú
Âü¼®¿¹»óÀοø : 700¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 12 ½Ã°£ 34ºÐ
¼¼ºÎ¼ö°·á : 100,000¿ø
ºñ°í »çÀüµî·Ï: Àü¹®ÀÇ, ÀϹÝÀÇ, ±³¼ö 8¸¸¿ø, Àü°øÀÇ, ±âŸ 4¸¸¿ø / ´çÀϵî·Ï: Àü¹®ÀÇ, ÀϹÝÀÇ, ±³¼ö 10¸¸¿ø, Àü°øÀÇ, ±âŸ 5¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-07 ±×·£µå ¿öÄ¿Èú ¼¿ï 08:00~09:00 Featured Abstracts I TBD(TBD)
ÈÞ½Ä 05-07 ±×·£µå ¿öÄ¿Èú ¼¿ï 09:00~09:10 ÈÞ½Ä ()
±³À°½Ã°£ 05-07 ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëA 09:10~09:40 Hypersensitivity to antineoplastic agents Mariana Castells(Harvard Medical School, USA)
±³À°½Ã°£ 05-07 ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëA 09:40~10:10 Cephalosporin allergy: current understanding and future challenges David Khan(UT Southwestern Medical Center, USA)
±³À°½Ã°£ 05-07 ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëA 10:10~10:40 Severe cutaneous adverse reactions: nationwide registry-based study in Korea °Çý·Ã(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05-07 ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëB 09:10~09:40 New findings of pathophysiology in pollen-food allergy syndrome Ebisawa Motohiro(Sagamihara National Hospital, Japan)
±³À°½Ã°£ 05-07 ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëB 09:40~10:10 Novel components to diagnose food allergy Nobuyuki Maruyama(Kyoto Univ., Japan)
±³À°½Ã°£ 05-07 ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëB 10:10~10:40 Immunotherapy in patients with pollen allergy ¹ÚÁß¿ø(¿¬¼¼ÀÇ´ë)
ÈÞ½Ä 05-07 ±×·£µå ¿öÄ¿Èú ¼¿ï 10:40~10:50 ÈÞ½Ä ()
±³À°½Ã°£ 05-07 ±×·£µå ¿öÄ¿Èú ¼¿ï 10:50~11:50 Featured Abstracts II TBD(TBD)
ÈÞ½Ä 05-07 ±×·£µå ¿öÄ¿Èú ¼¿ï 11:50~12:00 ÈÞ½Ä ()
±³À°½Ã°£ 05-07 ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëA 12:00~12:40 Omalizumab as the first biologics for severe asthma and CRSwNP ÀÌÀçÇö(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05-07 ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëB 12:00~12:40 Optimal approach for the treatment of severe asthma; benralizumab Andrea Matucci(Careggi University, Italy)
ÈÞ½Ä 05-07 ±×·£µå ¿öÄ¿Èú ¼¿ï 12:40~13:00 ÈÞ½Ä ()
±³À°½Ã°£ 05-07 ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëA 13:00~13:30 Insights into chronic urticaria for diagnosis and management Michihiro Hide(Hiroshima Univ., Japan)
±³À°½Ã°£ 05-07 ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëA 13:30~14:00 The international WAO/EAACI guideline for the management of hereditary angioedema (virtual) Yuxiang Zhi(Peking Union Medical College Hospital, China)
±³À°½Ã°£ 05-07 ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëA 14:00~14:30 Current and emerging biologics for the treatment of atopic dermatitis À̵¿ÈÆ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05-07 ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëB 13:00~13:22 PM & asthma exacerbation: How to measure personal exposure? ¼Û´ëÁø(°í·ÁÀÇ´ë)
±³À°½Ã°£ 05-07 ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëB 13:22~13:44 Impact of PM on the respiratory system and the effective strategy to avoid its exposure À̼¼¿ø(¿ï»êÀÇ´ë)
±³À°½Ã°£ 05-07 ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëB 13:44~14:02 Toxic inhalation and asthma: lessons from humidifier disinfectant (KAAACI) ÀÌÁ¾ÀÎ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 05-07 ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëB 14:02~14:24 Environmental and genetic factors in COPD ±è¿ìÁø(°¿øÀÇ´ë)
ÈÞ½Ä 05-07 ±×·£µå ¿öÄ¿Èú ¼¿ï 14:30~14:40 ÈÞ½Ä ()
±³À°½Ã°£ 05-07 ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëA 14:40~15:00 Endotyping is the answer in the treatment of CRS: Pros ±è´ë¿ì(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05-07 ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëA 15:00~15:20 Endotyping is the answer in the treatment of CRS: Cons Á¶ÇüÁÖ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05-07 ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëB 14:40~15:00 As-needed ICS-formoterol ±èÁÖÈñ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 05-07 ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëB 15:00~15:20 As-needed ICS-formoterol ±ÇÀç¿ì(°¿øÀÇ´ë)
ÈÞ½Ä 05-07 ±×·£µå ¿öÄ¿Èú ¼¿ï 15:20~15:30 ÈÞ½Ä ()
±³À°½Ã°£ 05-07 ±×·£µå ¿öÄ¿Èú ¼¿ï 15:30~16:00 Novel therapeutics harnessing microbial extracellular vesicles in allergic diseases ±èÀ±±Ù(MDÇコÄɾî)
±³À°½Ã°£ 05-07 ±×·£µå ¿öÄ¿Èú ¼¿ï 16:00~16:30 Concept of one health for allergy and asthma Ioana Agache(Transylvania Univ., Romania)
ÈÞ½Ä 05-07 ±×·£µå ¿öÄ¿Èú ¼¿ï 16:30~16:40 ÈÞ½Ä ()
±³À°½Ã°£ 05-07 ±×·£µå ¿öÄ¿Èú ¼¿ï 16:40~17:10 Climate change and pollen allergy ¿ÀÀç¿ø(ÇѾçÀÇ´ë)
±³À°½Ã°£ 05-07 ±×·£µå ¿öÄ¿Èú ¼¿ï 17:10~17:40 Updated ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines Marek Jutel(Wroclaw Medical Univ., Poland)